News

Cagrilintide is an amylin analog currently under development, intended to be used in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in individuals with overweight and obesity. In clinical trials, cagrilintide has shown significant weight loss effects when used alone or in combination with semaglutide. This combination medication, known as CagriSema, is a recombinant and synthetic peptide commercialized by Novo Nordisk, with a leading Phase III program targeting Type 2 Diabetes.

Cagrilintide mimics the action of amylin, a hormone produced by the pancreas that promotes feelings of satiety or fullness after eating. It is a non-selective agonist formulated at low pH for subcutaneous injection once a week. The molecule is based on the human amylin backbone, inspired by calcitonin, and has a prolonged action profile due to reversible albumin binding, similar to semaglutide. The development focuses on chemical modifications to enhance its stability, potency, and biological half-life. Participants in the trials reported some gastrointestinal side effects, such as nausea and vomiting.